In this interview, Michael Reitermann, CEO, Siemens Healthcare Diagnostics, discusses the company’s latest central laboratory systems with the SelectScience Clinical Diagnostics Editor, Sonia Nicholas.
Exclusive Interview: Michael Reitermann Discusses New Central Lab Systems from Siemens
SN: You unveiled two new central laboratory systems at the AACC Clinical Lab Expo last week. Could you briefly describe these new systems for us?
The ADVIA® Chemistry XPT1
System and ADVIA Centaur® XPT Immunoassay System2
are new central laboratory analyzers that are designed to support continuous operations, enhance workflow and streamline processes to help customers quickly, reliably and cost-effectively meet ever-increasing workload demands.
Specifically, harmonized, intuitive software, large touchscreens and Siemens Remote Service diagnostics will support easy operations. Also, each system features versatile technology that will enable a broad range of testing to support clinicians in disease screening, diagnosing and monitoring.
In addition, both systems are designed for automation—including our Aptio Automation Solution—no additional robotics needed. Enhanced data management capability will also be achieved with our CentraLink™ Data Management System. SN: What sized laboratories are these systems aimed at? MR:
The ADVIA Chemistry XPT System is a fast system for the high-volume laboratory, with a throughput of up to 2400 tests per hour. Predictable turn-around times are achieved by the combination of micro-volume technology and aliquot retention. Sample aliquots are readily available onboard for testing and retesting. There is no need to return the tube to the system. The VeriSmart® Technology is a combination of hardware and software checks to ensure high quality results.
The ADVIA Centaur XPT Immunoassay System is designed to process up to 240 tests per hour, upload test definitions on demand, and provide uninterrupted processing even when loading and unloading samples, reagents and supplies. The system is intended to require very little maintenance. SN: What effect could these analyzers have on laboratory efficiency and LEAN working?
The ADVIA Chemistry XPT System and ADVIA Centaur XPT Immunoassay System are designed to enhance laboratory efficiency by enabling continuous, simplified operations. When connected to Siemens’ Automation Solutions, parallel processing capability will expedite sample management and provide predictable, consistent turn-around times. The harmonized, intuitive software will allow for ease of use and ease of training, individually and across the analyzers. SN: You also showcased a new point-of-care coagulation analyzer at the recent IFCC WorldLab 2014 in Istanbul, Turkey, a few weeks ago. Can you tell us more about this analyzer and the technology that it employs? MR:
The Xprecia Stride™ Coagulation Analyzer2
is a compact, ergonomic hand-held analyzer that is engineered for ease of use. It is designed to perform prothrombin time testing (PT/INR) and to deliver results within minutes at the point of care. The technology we are using in the test strip and the analyzer is aimed at enhancing testing efficiency and the overall user experience. SN: What benefits does this analyzer offer to your customers? MR:
The Xprecia Stride Coagulation Analyzer was designed to meet many of the challenges faced by professionals today in POC coagulation testing. The system was designed with usability in mind, and several system components were created specifically to improve ease of use. We also aim to address safety concerns with a test strip eject button so that users do not have to touch used test strips. Finally, to help enhance testing efficiency, the overall system and test strip design is intended to facilitate efficient sample acquisition.
1. Product availability varies by country
2. Under development. Not available for sale. Product availability may vary from country to country and is subject to regulatory requirements.
Image Caption: Michael Reitermann, Chief Executive Officer, Siemens Healthcare Diagnostics Inc.
Executive Biography: On May 1, 2010, Michael Reitermann assumed the role of CEO, Siemens Healthcare Diagnostics Inc. In this position, Mr. Reitermann is responsible for the Diagnostics division of Siemens Healthcare. Mr. Reitermann is based in Tarrytown, NY. Mr. Reitermann’s passion for science and technology has driven his extensive career with Siemens. In his previous role Mr. Reitermann was responsible for the U.S. imaging organization. Before that assignment, he served as CEO of the Siemens Molecular Imaging Business Unit. Mr. Reitermann was responsible for the establishment and implementation of the Molecular Imaging’s business objectives around the world, as well as the Business Unit’s overall financial performance. During his tenure, Siemens launched the Symbia, Biograph Truepoint, and Biograph mCT product lines.
Company websiteSiemens Healthcare Diagnostics